I'm LongbridgeAI, I can summarize articles.Satellos Bioscience announced six-month interim TRAILHEAD data for SAT-3247 in adult DMD patients. Results showed improved muscle fat fraction (down 3.7%) and higher upper-limb effort (up ~34%). Handgrip strength gains were maintained, and mean CK declined 38%. The safety profile remained favorable with no serious adverse events. A conference call is scheduled for July 8.
- Satellos released six-month interim TRAILHEAD data for SAT-3247 in adult DMD patients, showing improved muscle fat fraction and higher upper-limb effort. * Mean muscle fat fraction fell 3.7% to 46% at month 6; TE99C rose about 34% to 21.6 joules/kg. * Handgrip strength gains seen in the earlier CL-101 study were maintained; mean CK declined 38% to 1,315 u/l. * Safety profile remained favorable, with no serious treatment-emergent adverse events or discontinuations. * Conference call and webcast scheduled for today, July 8 at 8:30 a.m. ET; live link here (here). Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Satellos Bioscience Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607080630PRIMZONEFULLFEED9758529) on July 08, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)